929 results on '"Zettl, Uwe K"'
Search Results
2. Patient-reported outcome parameters and disability worsening in progressive multiple sclerosis
3. Side effects following vaccination in multiple sclerosis: a prospective, multi-centre cohort study
4. Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.
5. New consensus guidelines on vaccination in multiple sclerosis
6. A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.
7. SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational study
8. Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart® Injector: Results of the Prospective Cohort Study REBIFLECT
9. Vaccination and immunotherapies in neuroimmunological diseases
10. Dentate-nucleus gadolinium deposition on magnetic resonance imaging: ultrasonographic and clinical correlates in multiple sclerosis patients
11. Trends in administrative prevalence of multiple sclerosis and utilization patterns of disease modifying drugs in Germany
12. Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity
13. Therapy Switches in Fingolimod-Treated Patients with Multiple Sclerosis: Long-Term Experience from the German MS Registry
14. Infektionen und Multiple Sklerose
15. Lethal form of a late-onset aquaporin-4 antibody-positive NMOSD related to the immune checkpoint inhibitor nivolumab
16. Characteristics of secondary progressive multiple sclerosis: Disease activity and provision of care in Germany – A registry-based/multicentric cohort study
17. Die Corona-Pandemie und Multiple Sklerose: Impfungen und deren Implikationen für Patienten – Teil 1: Empfehlungen
18. Die Corona-Pandemie und Multiple Sklerose: Impfungen und deren Implikationen für Patienten – Teil 2: Impfstofftechnologien
19. Krankheitsverlauf und Prognose
20. Autorenverzeichnis
21. Epidemiologie
22. Molekularbiologische Untersuchungen bei MS
23. Risikomanagement und alltagspraktische Aspekte
24. Sequenzen verlaufsmodifizierender Therapie
25. Genetik, Umwelt- und Lifestyle-Faktoren
26. Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper)
27. General Principles of Immunotherapy in Neurological Diseases
28. Is benign MS really benign? What a meaningful classification beyond the EDSS must take into consideration
29. Explorative study of emerging blood biomarkers in progressive multiple sclerosis (EmBioProMS): Design of a prospective observational multicentre pilot study
30. Merits and culprits of immunotherapies for neurological diseases in times of COVID-19
31. Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study
32. Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry
33. Kopfschmerzen bei Multipler Sklerose
34. Risiken und Chancen von Immuntherapien in Zeiten der Coronavirus-2019-Pandemie
35. Chances and challenges of a long-term data repository in multiple sclerosis: 20th birthday of the German MS registry
36. A smart peek: Processing of rapid visual displays is disturbed in newly diagnosed, cognitively intact MS patients and refers to cognitive performance and disease progression in late stages
37. CSF Findings in Acute NMDAR and LGI1 Antibody–Associated Autoimmune Encephalitis
38. Polypharmacy in patients with multiple sclerosis and the impact on levels of care and therapy units
39. Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis
40. Longitudinal prevalence and determinants of pain in multiple sclerosis: results from the German National Multiple Sclerosis Cohort study
41. Varicella-zoster- und Herpes-zoster-Impfindikation bei Multipler Sklerose: aktuelle Situation
42. Headache in the course of multiple sclerosis: a prospective study
43. Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS)
44. Information processing deficits as a driving force for memory impairment in MS: A cross-sectional study of memory functions and MRI in early and late stage MS
45. Spasticity in multiple sclerosis: Contribution of inflammation, autoimmune mediated neuronal damage and therapeutic interventions
46. Costs and Quality of Life in Multiple Sclerosis: An Observational Study in Germany
47. Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis.
48. Polypharmacy in patients with multiple sclerosis and the impact on levels of care and therapy units.
49. Kapitel 35 - Lebensstil und neurologische Erkrankungen
50. Kapitel 14 - Neurologische Erkrankungen und Impfungen gegen Infektionskrankheiten
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.